- Home
- KIM vs ROIV Comparison
KIM vs ROIV Comparison
Compare KIM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KIM | ROIV |
|---|---|---|
| Founded | 1958 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 14.1B |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | KIM | ROIV |
|---|---|---|
| Price | $20.59 | $21.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $24.17 | ★ $24.31 |
| AVG Volume (30 Days) | 4.5M | ★ 8.4M |
| Earning Date | 02-12-2026 | 02-09-2026 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | ★ 57.13 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $2,123,057,000.00 | $20,329,000.00 |
| Revenue This Year | $5.60 | N/A |
| Revenue Next Year | $3.39 | $741.42 |
| P/E Ratio | $24.42 | ★ N/A |
| Revenue Growth | ★ 8.14 | N/A |
| 52 Week Low | $17.93 | $8.73 |
| 52 Week High | $23.65 | $23.47 |
Technical Indicators
Market Signals| Indicator | KIM | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 56.08 | 53.52 |
| Support Level | $19.97 | $21.15 |
| Resistance Level | $20.46 | $22.14 |
| Average True Range (ATR) | 0.28 | 0.65 |
| MACD | 0.05 | -0.13 |
| Stochastic Oscillator | 84.38 | 52.76 |
Price Performance
Historical ComparisonAbout KIM Kimco Realty Corporation (HC)
One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 567 shopping centers throughout major markets in the US, representing roughly 101 million square feet.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.